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ABSTRACT: Tau neurofibrillary tangles are key pathological features
of Alzheimer’s disease and other tauopathies. Recombinant protein
technology is vital for studying the structure and function of tau in
physiology and aggregation in pathophysiology. However, open-source
and well-characterized plasmids for efficiently expressing and purifying
different tau variants are lacking. We generated 44 sequence-verified
plasmids including those encoding full length (FL) tau-441, its four-
repeat microtubule-binding (K18) fragment, and their respective
selected familial pathological variants (N279K, V337M, P301L,
C291R, and S356T). Moreover, plasmids for expressing single
(C291A), double (C291A/C322A), and triple (C291A/C322A/
I260C) cysteine-modified variants were generated to study alterations
in cysteine content and locations. Furthermore, protocols for
producing representative tau forms were developed. We produced and characterized the aggregation behavior of the triple
cysteine-modified tau-K18, often used in real-time cell internalization and aggregation studies because it can be fluorescently labeled
on a cysteine outside the microtubule-binding core. Similar to the wild type (WT), triple cysteine-modified tau-K18 aggregated by
progressive β-sheet enrichment, albeit at a slower rate. On prolonged incubation, cysteine-modified K18 formed paired helical
filaments similar to those in Alzheimer’s disease, sharing morphological phenotypes with WT tau-K18 filaments. Nonetheless,
cysteine-modified tau-K18 filaments were significantly shorter (p = 0.002) and mostly wider than WT filaments, explainable by their
different principal filament elongation pathways: vertical (end-to-end) and lateral growth for WT and cysteine-modified, respectively.
Cysteine rearrangement may therefore induce filament polymorphism. Together, the plasmid library, the protein production
methods, and the new insights into cysteine-dependent aggregation should facilitate further studies and the design of antiaggregation
agents.
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■ INTRODUCTION
The microtubule (MT) associated protein tau (MAPT) gene,
which encodes the tau protein, is located on chromosome
17q21.1,2 MAPT comprises 16 exons some of which are
alternatively spliced to generate tau isoforms that are
differentially expressed in tissues and in development.3,4 The
adult human brain has six tau isoforms produced from the
alternative splicing of exons 2, 3, and 10.1,5 Tau is comprised of
a number of regions: the N-terminal projection domain,
proline-rich domains in the midregion, and the C-terminal
assembly domain, the latter containing the MT binding region
[MTBR] and the C-terminus, separated by two proline-rich
regions.1,5 The isoforms can be distinguished by the number of
alternatively spliced inserts at the N-terminus (0, 1, or 2 N-
terminus inserts) and in the MTBR (3 or 4 MTBR repeats).1,5
In normal adult humans, a 1:1 ratio of 4R to 3R is maintained.6
However, this isoform balance is disturbed in pathophysio-
logical conditions, with tauopathies biochemically categorized
based on their tau isoform composition. Primary tauopathies
(including corticobasal degeneration, progressive supranuclear
palsy, and globular glial tauopathy) tend to have 4R tau
isoforms (except Pick’s disease with 3R tau), while secondary
tauopathies such as Alzheimer’s disease (AD) and chronic
traumatic encephalopathy have a mix of 3R and 4R
isoforms.7−11 The alternative splicing of exon 10 has been
particularly linked to several tauopathies since it affects the
ratio of three-repeat (3R) to four-repeat (4R) tau isoforms.12
The most-studied physiological function of tau is its support
of axonal transport by binding to and modulating the stability
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of MTs.13,14 Tau binds to MTs at the α- and β-tubulin
heterodimer interface using specific amino acid sequences,
most of which are located within the MTBR.15 This generates
a local hairpin structure involving the hexapeptide motifs
275VQIINK280 and 306VQIVYK311, with numbering correspond-
ing to 441 amino acid-long full-length (FL) tau (Uniprot
#P10636-8).15 Over 110 single nucleotide polymorphisms in
MAPT have been reported, with more than a dozen associated
with specific familial forms of frontotemporal dementia
(FTD).16−19 Several of these disease-associated mutations
can interfere with the protein’s MT-binding function, by either
potentiating or decreasing this activity.20−22 How specific
MAPT mutations cause distinct effects on tau’s MT
interactions are not clearly understood, with further studies
needed.
In disease conditions, tau can become hyperphosphorylated
on specific residues leading to its detachment from MTs,
thereby compromising axonal transport/assembly.23 Following
this loss of function, the soluble, unfolded phosphorylated tau
proteins can self-polymerize to eventually form paired helical
filaments (PHFs) and other filamentous aggregates enriched in
β-sheet structures, via oligomer and protofibril intermediates.24
These filaments are critical components of neurofibrillary
tangles (NFTs), which are hallmarks of AD and other
tauopathies.24,25 Tau aggregation can also occur through
disulfide interactions involving the native cysteine residues,
either at position 291 only (3R isoforms) or at 291 and 322
(4R isoforms).26−28 Intermolecular disulfide bonding is
thought to promote aggregation, while intramolecular bonding
inhibits aggregation.29 4R tau isoforms can therefore aggregate
faster than 3R tau isoforms, possibly due to their capacity to
form increasing polymers of disulfide-bonded aggregates
relative to 3R tau isoforms whose disulfide-dependent
aggregation is limited to dimerization.30 However, the
aggregation-prone 275VQIINK280 hexapeptide motif in 4R,
but not 3R, tau isoforms may also contribute to the observed
higher aggregation tendency of 4R tau, although little
investigation has focused on this hypothesis.31,32
Tau aggregation requires at least one of the hexapatide
motifs 275VQIINK280 and 306VQIVYK311 within the
MTBR.31,33,34 Notably, a number of familial FTD-associated
MAPT mutations, again located in the MTBR (e.g., P301L,
V337M, N279K), are known to either accelerate or decrease
tau aggregation kinetics and can form filaments of distinct
structural phenotypes compared to the wild type (WT).20−22,35
Furthermore, some disease-associated mutations demonstrate
stark differences in their ability to be “seeded” by filaments
from the WT 4R tau MTBR (the K18 fragment), with P301L
and P301S exhibiting robust template misfolding capabil-
ities.35,36 This suggests that tau aggregation is conformation-
dependent and that selected MAPT mutations may affect
aggregation through distinct mechanisms. Moreover, the
temporal and spatial progression of tau aggregate accumulation
in AD and other tauopathies, which correlates well with
cognitive decline, is thought to occur as a result of intercellular
transfer and seeding of tau aggregates in cells.37,38 Specific
MAPT mutations can influence this process through distinct
effects on exogenous tau internalization and release.35,39
Moreover, tau aggregation can be a downstream event in AD
(especially evident in familial AD due to mutations in the APP
and PSEN genes), as well as in some other disorders (e.g.,
Niemann-Pick type C).40 Together, these data demonstrate
that aggregation is a critical determinant of the pathophysio-
logical functions of tau.
Much of the insight into the physiological and pathophysio-
logical functions of tau (including MT binding, aggregation,
and intercellular propagation) has been obtained using tau
from recombinant sources, with many of these processes
corroborated using human or animal tissues.22,23,41−45 These
data establish recombinant technology as a validated strategy
for generating functional tau proteins whose properties closely
align with those of human brain tau protein. However,
recombinant preparation of tau can be challenging and time-
consuming, given that one needs to design and verify gene and
plasmid sequences and perform polymerase chain reaction
(PCR), restriction digestion, and ligation, before transforming
a host of choice for expression. Even though some of these
problems can be addressed by plasmid sharing between
laboratories, the recipients often have to develop and optimize
their own expression and purification protocols. These
bottlenecks can unduly delay the preparation of recombinant
tau. In an attempt to help address these shortcomings, we have
generated a library of 44 sequence-verified plasmids for
expressing FL human tau-441 (the longest tau isoform in the
adult human brain) and truncated tau consisting of the 4R
MTBR fragment (K18). These include plasmids for producing
specific FTD variants of FL and K18 tau (V337M, N279K,
P301L, C291R, and S356T), as well as cysteine-modified
variants (C291A, C291A/C322A, C291A/C322A/I260C) of
the FL and K18 fragment of WT and FTD tau variants.
Since FL 4R tau contains two native cysteine residues,28
single and double cysteine modifications (usually replaced by
alanine or serine) allow for studies of contributions of one or
both native cysteine residues to the protein’s properties of
interest (MT binding, stabilization, and polymerization;46,47
filamentous aggregation and associated conformational
changes26,28,48−52). For studies aimed at investigating incipient
tau aggregation and the intercellular propagation and toxicity
of extracellular tau using real-time and/or kinetic assays,
maleimide-based fluorophore labeling is, however, often used.
This technique, first introduced by the Mandelkow groups,53,54
often involves triple cysteine modification where the native
cysteine residues are removed (C291A/C322A) and a new
cysteine residue introduced outside the central core of the
MTBR (I260C) to minimize or avoid steric hin-
drance.35,49,53−58 Notwithstanding its increasing popularity, it
has not been well studied if this triple cysteine modification
affects tau aggregation kinetics, filament formation, and
secondary structure. Importantly, answering this question will
help provide a validated context to interpreting outcomes of
experiments using these constructs. We therefore took
advantage of the plasmid resources and the expression and
purification methods developed to generate and carefully
analyze the aggregation and Alzheimer-like filament formation
paths and products of K18 C291A/C322A/I260C and K18
WT.
■ RESULTS AND DISCUSSION
Construction and Verification of Plasmids for
Expressing FL and Truncated Tau and Their Respective
Selected FTD Variants. pProEx-HTa plasmids encoding
human WT FL or K18 tau (Figure S1) were created, and their
sequences were verified by DNA sequencing. The coding
sequences derived from the amino acid sequence for tau 1-441
(Uniprot #P10636-8) were generated by PCR from template
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pCMV-tau plasmids and cloned into the EheI and EcoRI
restriction sites of the pProEx-HTa plasmid as previously
described.59 DNA sequencing was performed externally by
GATC Biotech AG, Konstanz, Germany. Protein expression
was controlled by a trc promoter. The plasmid description is
available in Table S1. Moreover, each plasmid had a cleavable
N-terminal 6xHis tag for purification by immobilized metal
affinity chromatography (IMAC; Figure S1). Each K18
plasmid also had a c-Myc tag inserted between the 6xHis tag
and the genetic construct of interest, while the FL tau plasmids
either had a C-terminus c-Myc tag or an N-terminus FLAG tag
downstream of the 6xHis tag (Figure S1 and Table S1).
Specific FTD mutations can alter the physiological
(including MT binding and stabilization and subcellular
localization21,60−62) and pathophysiological (e.g., phosphor-
ylation, aggregation pathway, kinetics, and prod-
ucts21,22,35,63−66) functions of tau. To increase the utility of
our genetic resource library, the template WT plasmids were
used to generate plasmids for expressing specific FTD variants
of FL and K18 tau. We focused on selected FTD mutations
spanning the MTBR, including some with relatively well
characterized biochemical properties (e.g., V337M, N279K,
and P301L21,36,65−69) and others about which little is known
(e.g., C291R and S356T70,71). Successful generation of these
constructs (Figure 1) was verified by DNA sequencing, with
the codon changes and site-directed mutagenesis primers listed
in Table S2.
Design and Verification of Plasmids for Expressing
Cysteine Variants of FL, Truncated, and FTD Tau. The
redox state of 4R tau, which has two native cysteine residues,
can critically influence its properties.28,46,47,72 To support
studies focused on understanding potential effects of the
availability, quantity, and location of cysteine residues on tau
functions, plasmids for expressing FL and truncated tau (both
WT and FTD variants) bearing single (C291A), double
(C291A/C322A), or triple (C291A/C322A/I260C) cysteine
modifications were further generated (Figure 2 and Table S1).
Codon changes made and primers used to generate these
variants can be found in Table S3, with DNA sequencing
primers in Table S4. Figure 3 shows a schematic illustration of
the first (FTD mutations) and second order (cysteine
modifications) plasmids generated based on each WT template
construct.
Expression and Purification of WT and Triple
Cysteine-Modified FL Tau. To help simplify recombinant
tau production, we developed a protocol for expressing and
purifying selected constructs from our plasmid library. We
adapted a high-yield method59 to produce the WT and triple
cysteine-modified forms of both FL tau and K18. Plasmids
Figure 1. Schematic illustration of FL and truncated tau plasmid
constructs carrying specific pathological MAPT mutations generated
in this study. (A) In addition to the template plasmid for expressing
WT FL tau-441, sequence-verified alternatives each carrying one of
the FTD variants N279K, C291R, P301L, and V337M were
constructed. The location of each pathological mutation in the
MTBR is shown. (B) Plasmid constructs encoding the WT K18
fragment (the MTBR only) and its variants carrying one of the
N279K, C291R, P301L, V337M, and S356T mutations created in this
study. The location of each mutation is indicated.
Figure 2. Schematic illustration of plasmid constructs created for the
expression of WT and FTD versions of FL and K18 proteins
containing specific cysteine modifications. Single (C291A), double
(C291A/C322A), and triple (C291A/C322A/I260C) cysteine
modifications in FL tau-441 (WT or FTD variants) are illustrated
in (A), (B), and (C), respectively. (D), (E), and (F) describe the
single, double, and triple cysteine modifications, respectively, in the
K18 group of plasmids created in this study. The dashed lines denote
the full length tau sequence which is removed in the truncated K18
construct.
Figure 3. Incremental generation of plasmids expressing tau protein
variants carrying specific FTD-associated mutations and cysteine
modifications. Template plasmids for expressing WT FL and
truncated tau were first created (A). Subsequently, mutagenesis of
these base plasmids was used to generate variants encoding specific
FTD mutations (B). Next, single, double, or triple cysteine
modifications were introduced in the primary (WT) and secondary
(FTD variants) plasmids to generate new forms of tau with variable
cysteine content (C).
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transformed into BL21(DE3)*pRosetta Escherichia coli were
expressed and purified by immobilized metal affinity
chromatography (IMAC), taking advantage of the cleavable
N-terminal 6xHis tags, as described (see the Methods section).
Expressed protein variants were initially purified by IMAC.
Tau-positive fractions, identified after SDS-PAGE and Western
blotting, were further purified by size exclusion chromatog-
raphy (SEC), and the purest fractions were selected (Figure 4).
Cleavage of the 6xHis tag was achieved by overnight dialysis in
the presence of tobacco etch virus (TEV) protease, followed
by a second IMAC purification resulting in the 6xHis tag
bound to the column, liberating the cleaved protein as either
tau-K18 with a c-Myc tag or FL tau-441 with a FLAG tag.59
The IMAC-purified 6xHis-tagged tau K18 fragments
migrated on SDS-PAGE gels with electrophoretic mobility
corresponding to ∼22 kDa and were recognized by the 77G7
(Figure 4A,B) and K9JA59 antitau antibodies both selective for
the MTBR (epitopes = amino acids (aa) 316−355 for 77G7
and 244−372 for K9JA). Cleavage of the 6xHis tag was
demonstrated by lost reactivity to the anti-His antibody,59
reducing the apparent molecular weight of the K18 peptides to
∼17 kDa by Western blotting (Figure S2). WT and triple
cysteine-modified FL tau were also purified to near
homogeneity with apparent sizes of ∼62 kDa on SDS-
PAGE/Western blot, with strong reactivity to the N-terminus
antitau antibody Tau12 (epitope = aa 6−18; Figure 4C,D) and
the MTBR-binding K9JA (Figure S3). For characterization of
purified tau species using SEC, see Figure S4.
Thioflavin T Assay Shows That Triple Cysteine
Modification Decreases the Aggregation Propensity
of WT Tau K18. A ThT assay was developed to study if the
triple cysteine modification affected the aggregation kinetics of
K18 WT. K18 WT had an initial mean signal of ∼1200 relative
fluorescent units (RFU), which after a lag phase of ∼1.5 h,
increased sharply until reaching a plateau at ∼11,400 RFU just
after 5 h (Figure 5A,B). On the contrary, K18 C291A/C322A/
I260C had severely reduced ThT kinetics: an initial mean
signal at ∼200 RFU increased slowly until reaching a peak at
∼600 RFU after 3 h (Figure 5A−C). The kinetic behavior of
K18 C291A/C322A/I260C was more visible by focusing on
RFU values < 800, which showed that the peptide had an
initial small increase in ThT fluorescence which immediately
stabilized after 3 h: no discernible lag phase was recorded
(Figure 5C). The data suggest that the triple cysteine
modification decreases the aggregation rate of tau K18 ∼20
fold in nonreducing conditions.
WT Tau K18 Forms Filaments Faster than Its Triple
Cysteine-Modified Variant. Co-incubation of amyloidogen-
ic proteins with the ThT dye can lead to unintended effects on
aggregation.73 To rule out the possibility that the decreased
aggregation kinetics of K18 C291A/C322A/I260C was due to
anomalous interactions with ThT, a dye-free aggregation assay
was performed. No filament formation was recorded for either
sample incubated for 15 h at 37 °C without shaking.
Consequently, the incubation time was extended to promote
filament assembly. After 5 days in the same conditions, K18
WT, but not K18 C291A/C322A/I260C, formed filamentous
aggregates (Figure 6A,B). This corroborates the ThT-
monitored aggregation data in Figure 5 that the triple cysteine
modification decreases the aggregation kinetics of K18 WT in
nonreducing conditions.
End Point Tau K18 Aggregates Have Converging and
Diverging Structural Phenotypes. Incubation time for
aggregation reactions was further increased to 16 days to
enable both tau variants to form mature filamentous
aggregates. TEM analysis showed that K18 WT and K18
C291A/C322A/I260C formed filaments with both converging
and diverging phenotypes. Both variants formed paired helical
filaments (PHFs) with varying degrees of twist (Figure 7Ai−
Figure 4. Expression and purification of WT FL and truncated tau
K18 and their triple cysteine modified variants. Representative
characterization of tau purification by Western blotting. K18 WT
(A) and K18 triple cysteine-modified (B) were analyzed by Western
blotting using the 77G7 antitau antibody (epitope = aa 316−355),
while the WT (C) and triple cysteine modified (D) FL tau were
probed with Tau12 (epitope = aa 6−18). A previous preparation of
WT recombinant FL tau-441 was used as a control on each blot. The
alphanumeric labeling of lanes refers to the analyzed fractions from
size exclusion chromatography that were analyzed by Western
blotting. Bands corresponding to tau which is in the conformation
of interest are indicated by black arrows. Fractions labeled in red were
the purest/highest yield selected for further processing. Figures S2
and S3 show Western blot characterization of the initial IMAC-based
purification. Size characterization of purified tau forms using SEC can
be found in Figure S4.
Figure 5. Aggregation kinetics of WT and triple cysteine-modified tau
K18 in the ThT fluorescence assay. (A) Aggregation kinetics of the
tau K18 variants each normalized to corresponding signals from the
constituent buffer only + ThT (negative control). Normalization was
achieved by subtracting the ThT signal generated by buffer only at
each time point from the signals generated by the tau K18 constructs.
Data are expressed as mean ± SEM, n = 4 and n = 11 for K18 WT and
K18 C291A/C322A/I260C, respectively. (B) Magnified image
focusing on values ≤ 3000 RFU to highlight the shape of the kinetic
curve for K18 C291A/C322A/I260C. (C) ThT fluorescence values ≤
800 RFU demonstrate that K18 C291A/C322A/I260C recorded a
brief rise in aggregation kinetics which then plateaued.
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iv,Bi−iv). In addition to classical PHFs (Figure 7Aiii,iv), K18
WT formed multistriated ribbons (multiple PHFs interwoven
together; Figure 8Ai) and ribbons with central depression
(multistriated ribbons of uneven widths; Figure 7Aii),
consistent with previous observations.74 Furthermore, a few
twisted filaments lacking the classical PHF arrangement were
observed (Figure 7Av). Moreover, in K18 WT preparations,
two types of straight (nontwisted) filaments (SFs) were
recorded: those with the regular linear appearance (Figure
7Avi) and others with a curved phenotype (Figure 7Avii,viii).
K18 C291A/C322A/I260C formed mostly PHFs which often
made lateral contacts with others and sometimes formed
clusters (Figure 7Bi−v). A few SFs were also observed (Figure
7Bvi).
WT tau K18 filaments were significantly longer than those of
K18 C291A/C322A/I260C (p = 0.002, two-tailed Mann−
Whitney test; mean lengths for WT and C291A/C322A/
I260C = 1457.00 ± 76.33 nm and 1069.00 ± 86.73 nm
respectively; Figure 8A). On the contrary, several K18 C291A/
C322A/I260C filaments appeared to be wider than those of
the WT (mean width for WT and cysteine-modified = 16.80 ±
1.27 nm and 20.38 ± 1.95 nm) although this difference was
not found to be significant (p = 0.376, two-tailed Mann−
Whitney test; Figure 8B). Careful observation of TEM images
suggested that contrary to filament growth for K18 WT, which
appeared to occur mainly through a vertical (end-to-end)
growth mechanism (due to their generally long and slender
morphology), K18 C291A/C322A/I260C had a lateral growth
mechanism evidenced by regular lateral contacts between
filaments, similar to those reported for amyloid β with an N-
terminal cysteine.75 Quantitatively, 90% (45/50) of fibrils
formed by K18 C291A/C322A/I260C made lateral contacts
with at least one other fibril. To the contrary, only 12% (5/41)
lateral contacts were recorded for K18 WT. Figure 8C shows a
typical TEM field of view for K18 WT filaments,
demonstrating their long appearance without lateral contacts.
Figure 8D shows an example of laterally interacting K18
C291A/C322A/I260C filament: wider but shorter than the
K18 WT filament in Figure 8C. Our finding of vertical growth
mechanism for K18 WT filaments is supported by a recent
study that demonstrated this mechanism for FL tau-441.76
Figure 6. Structural characterization of tau K18 aggregation products
in 5-day aggregation reactions. Representative TEM micrographs for
tau K18 WT (A) and K18 C291A/C322A/I260C (B). Images were
taken using identical TEM settings at 25000× magnification. Scale
bars = 100 nm.
Figure 7. Characterization of the aggregation products of tau K18
variants after 16 days of incubation. Representative TEM micrographs
for tau K18 WT (A) and K18 C291A/C322A/I260C (B) are shown,
demonstrating both shared and distinct morphological features
between filaments formed by the two constructs. Images were taken
using identical TEM settings at 12000× magnification. Scale bars =
100 nm for each panel.
Figure 8. Quantitative characterization of K18 WT and K18 C291A/
C322A/I260C filaments. (A) Box plot of filament lengths for the two
tau K18 variants. Two-tailed Mann−Whitney test, ** = p = 0.002.
Mean lengths for WT and cysteine-modified K18 filaments = 1457.00
± 76.33 nm and 1069.00 ± 86.73 nm, respectively. Median lengths
for K18 WT and K18 C291A/C322A/I260C = 1515.00 and 1038.00
nm, respectively. The filament length analysis included n = 21 data
points for K18 WT and n = 19 for K18 C291A/C322A/I260C. (B)
Box plot of filament widths for the tau K18 variants. Two-tailed
Mann−Whitney test, p = 0.376; ns = not significant. Mean widths for
K18 WT and K18 C291A/C322A/I260C = 16.80 ± 1.27 nm and
20.38 ± 1.95 nm, respectively. Median widths = 16.07 and 17.05 nm
for K18 WT and K18 C291A/C322A/I260C, respectively. The
filament width analysis included n = 22 data points for K18 WT and n
= 28 for K18 C291A/C322A/I260C. (C) (i) An example TEM image
showing the long and slender appearance of the K18 WT filament.
The image shown here has a length of 1966.59 nm and a width of 5.68
nm. Position where the width measurement was taken is marked “a”.
(ii) A digitally zoomed image highlighting the long and thin
appearance of the filament structure shown in (i). (D) (i) A
representative TEM micrograph demonstrating lateral connections
between two K18 C291A/C322A/I260C filaments. The upper
sections of these filaments had coalesced to form a thicker filament.
The filament on the left is 1038.08 nm long and 36.16 nm wide
(position marked “a”), while the one on the right is 1519.06 nm long
and 22.72 nm wide (position marked “b”). The width at the point of
coalescence (marked “c”) is 48.30 nm. (ii) Digital zoom showing a
magnified view of the lateral interactions observed in (i). The images
in (C)(i) and (D)(i) were both acquired using identical TEM settings
on the same day at 12000× magnification.
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Aggregation of Triple Cysteine-Modified Tau K18 Is
Characterized by Increased β-Sheet Structures. It is well-
known that the aggregation of K18 WT results in secondary
structure rearrangement toward ordered β-sheet conform-
ers.53,59,77,78 We therefore investigated if K18 C291A/C322A/
I260C also had this property. K18 C291A/C322A/I260C
monomers had negative CD spectra with the mean minimum
peak at 199.00 ± 0.55 nm, similar to that of K18 WT at 200.70
± 0.15 nm (Figure S5A,B), suggesting predominant random
coil conformations59,77,78 and indicating that the triple cysteine
modification does not alter the unfolded structure of tau K18
monomers. Following heparin-induced aggregation without
shaking, the K18 C291A/C322A/I260C spectra shifted toward
longer wavelengths, with new mean peaks of 202.90 ± 1.07 nm
at day 4 and 206.90 ± 0.03 nm at day 8 (Figure 9A and Table
S5). Insoluble aggregates (resuspended pellets) had negative
spectra with a mean peak at 224.00 ± 1.10 nm (Figure 9B and
Table S6). The K18 C291A/C322A/I260C insoluble
aggregate fraction consisted of abundant filaments (Figure
9C), including SFs (Figure 9D) and PHFs (Figure 9F) and
laterally interacting filaments (Figure 9E) similar to those
described in Figures 7 and 8. Together, β-sheet content in K18
C291A/C322A/I260C increased progressively with aggrega-
tion.
■ CONCLUSION
The preparation of recombinant forms of tau requires
sequence-verified plasmids for overexpressing the protein in
suitable expression hosts such as E. coli.59,79,80 The main aim of
this study was to design, produce, and characterize a large
library of plasmids to simplify the preparation of recombinant
FL and truncated tau protein variants. A total of 44 sequence-
verified plasmids were generated. These include plasmids for
expressing WT and FTD tau (V337M, N279K, P301L, C291R,
S356T) and their respective cysteine-modified variants
(C291A, C291A/C322A, C291A/C322A/I260C) on FL and
K18 backgrounds. Moreover, we have established protocols
that ensure high-level expression and also demonstrate the
purification and initial biochemical characterization of a
representative selection of FL and truncated tau genetic
constructs.
In this study, we focused on FL tau-441 and K18, both of
the 4R tau background. More than 110 MAPT mutations have
been described, with more of such mutations occurring in 4R
than 3R tau isoforms.19 4R tau has superior MT binding ability
compared with 3R tau14 and is a common constituent of PHFs
and NFTs isolated from the brains of individuals who died
with many forms of neurodegenerative tauopathies.67,81−83
Moreover, truncation of 4R tau into fragments containing
whole or part of the MTBR is a post-translational modification
with probable biomarker importance.84,85 4R tau therefore
offers an opportunity to study the molecular origins of MT
binding, aggregation, and filament formation, with direct
relevance to the protein’s physiological and pathophysiological
functions.
Verified Plasmids and Protocols for Expressing and
Purifying FL and Truncated Tau. Our comprehensive
plasmid library is meant to help address common bottlenecks
in plasmid sharing by providing ready-to-use genetic resources
with accompanying protocols for generating FL and truncated
tau variants. With the described protocols, the expression and
purification process is achievable in 2 or 3 days for 6xHis-
tagged and 6xHis tag-free tau, respectively, far shorter than
other published protocols.79,80 We expect that this first-of-a-
kind open access genetic resource library and the accompany-
ing methods will facilitate further studies. The expression and
purification protocols described are representative for the FL
and truncated tau forms created, as demonstrated above for the
cysteine-modified constructs and previously for the N279K,
V337M, and C291R variants.35,58,59,86
Impact of Triple Cysteine Modification on Tau K18
Aggregation and Filament Formation. Commonly used
fluorescent protein tags such as green fluorescent protein can
lead to unintended cellular effects,87,88 which in addition to
their large molecular weights (∼27 kDa) makes them unideal
as reporter systems for internalization and release of exogenous
tau. For this reason, the triple cysteine-modified forms of tau
have become an increasingly popular set of tools for studying
the aggregation, cellular internalization, release, and prop-
agation of these proteins in real time because of the advantage
of labeling a single cysteine residue located outside the MTBR
with fluorescent compounds.49,53−57 In addition, we recently
reported that specific labeling of triple cysteine-modified tau
K18 with the maleimide derivatives N-ethyl maleimide or
Alexa Fluor C3-maleimide in cold conditions generates stable
Figure 9. Aggregation of tau K18 C291A/C322A/I260C is
characterized by progressive β-sheet enrichment. (A) CD analysis of
time-dependent secondary structure changes in tau K18 C291A/
C322A/I260C during aggregation. Mean negative peak signals
increased from 196.60 ± 0.71 nm at day 0 to 202.90 ± 1.07 nm
and 206.90 ± 0.03 nm at days 4 and 8, respectively. The inset image
highlights peak intensity transition from day 4 to day 8. Each plot
shows the mean of n = 3 repeats with quantitative data given in Table
S5. (B) Mean CD spectrum of secondary structure content of the
insoluble fraction of aggregated tau K18 C291A/C322A/I260C
showing peak intensity at 224.00 ± 1.10 nm (n = 2, quantitative data
provided in Table S6). The inset highlights the spectrum peak on a
shorter vertical axis. (C) TEM characterization of the insoluble
aggregate fraction from (B). Similar to data shown in Figures 8 and 9,
K18 C291A/C322A/I260C formed a mix of PHFs and SFs. The
images in (D), (E), and (F) are zoomed in regions from (C). Scale
bars = 100 nm.
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tau oligomers suitable for biochemical, cellular, and electro-
physiological studies.35,58,89,90 However, it is unknown how the
in vitro aggregation mechanism compares to that of K18 WT.
We therefore took advantage of the resources and methods
created to investigate potential effects of the triple cysteine
modification on the aggregation paths and products of tau
K18. Some earlier studies reported that 4R tau isoforms have
decreased aggregation kinetics compared to 3R isoforms,
which may be due to the two native cysteine residues in 4R tau
forming aggregation-incompetent intramolecular disulfide
bonds (the so-called compact monomer conformation).29
However, others have argued that intramolecular disulfide
bonds may not have significant effects on 4R tau aggregation
and filament formation.49,52 Here, we sought to help address
this unresolved question by studying if the number of cysteine
residues influences tau K18 aggregation kinetics and filament
structure. While some previous studies have compared 3R and
4R tau isoforms and constructs directly,29 the deletion of an
entire repeat domain may have affected their experimental
outcomes, for instance, given the crucial pro-aggregation role
of the 275VQIINK280 hexapeptide motif in the second repeat
domain which is absent in 3R tau.31,91 Given that the K18
region is required for both disulfide-dependent and disulfide-
independent tau aggregation,92 we studied the double-cysteine
WT fragment and its C291A/C322A/I260C single-cysteine
variant which differ in the number of cysteine residues.
Although we cannot rule out potential effects of cysteine
positional changes in this variant, the present study was
focused on understanding disulfide bonding contributions to
tau K18 aggregation based on the number of cysteine residues.
This enabled detailed biochemical characterization of the in
vitro aggregation properties of K18 C291A/C322A/I260C.
Our findings indicate that tau K18 WT, with two cysteine
residues, aggregates into filaments more rapidly than its single-
cysteine variant. This is in agreement with a previous study
which demonstrated that the 3R FL tau (which has a single
native cysteine) forms less abundant dimers and higher order
oligomers compared to the 4R FL tau.92 An explanation for
this result is that as K18 C291A/C322A/I260C contains a
single cysteine, it can only form disulfide-dependent dimers
without disulfide-dependent higher-order aggregates compared
to the WT which can aggregate into larger structures via the
disulfide-dependent pathway27 (Figure 10). K18 WT therefore
had a faster aggregation due to combined effects of disulfide-
dependent and -independent aggregation processes compared
to K18 C291A/C322A/I260C with weaker disulfide-depend-
ent activity.
An alternative interpretation for our results is that the ability
of tau K18 to form filamentous aggregates is independent of
whether a cysteine residue is located within the first, second, or
third repeat domains. Previous studies on the contribution of
disulfide bonds to 4R tau aggregation modified single or
double cysteine residues to nonpolar amino acids like
alanine.26−28,51 Nonetheless, effects of introducing cysteine
residues outside the second and third repeat domains have
hitherto been unknown. We have shown here that restricting
cysteine residues to the second and third repeat regions (for
K18 WT) is not a requirement for Alzheimer-like filament
formation in vitro. Rather, aggregation characterized by β-
sheet-dependent filament assembly is attainable, although at a
reduced rate, when a single cysteine residue is placed in the
first repeat domain.
An important finding from this study is that a specific
rearrangement of native cysteine residues resulting in a single
cysteine outside the MTBR can drastically decrease the
aggregation kinetics and delay filament assembly in tau K18.
Similarly, modification of the C291 residue of K18 WT to
serine inhibited the peptide’s oligomerization competence.27
The strategy of modifying cysteine residues may therefore
inform the design of effective approaches to inhibit 4R tau
aggregation. Compared to the computer-guided random amino
acid shuffling approach used to generate aggregation-
compromised scrambled proteinopathic proteins,93,94 cysteine
modification is a more reproducible strategy that uses a
nonpharmacological approach to inhibit tau K18 aggregation,
with its effectiveness independent of external agents. Given the
physiological and pathophysiological importance of 4R
tau,16,95,96 a viable approach to block its disease-driving
aggregation will be useful for targeting most tauopathies.
The observed similarities and differences in filament
morphology for K18 WT and K18 C291A/C322A/I260C
suggest that the two protein variants have both shared and
divergent conformational changes leading to filamentous
aggregation. The mechanisms underlying these similar-yet-
diverse properties are not currently understood. However, a
few features stand out. K18 WT mostly formed long and thin
filaments. Filament assembly by this peptide involved vertical
association between two short filaments, as also reported in a
different study.76 In contrast, K18 C291A/C322A/I260C
filament elongation was dominated by lateral interactions of
filaments. As demonstrated by TEM imaging (Figure 8D),
coalescence of laterally associated filaments appeared respon-
sible for the generally wide nature of the resulting mature
filaments and may explain the frequently short appearance of
K18 C291A/C322A/I260C filaments. Importantly, the lateral
growth mechanism has been described for amyloid β with an
N-terminal cysteine,75 which highlights the importance of a
single cysteine residue for this aggregation pathway. To our
Figure 10. A proposed model of cysteine-dependent tau K18
aggregation in nonreducing conditions. (A) Monomeric tau K18
WT, with its two native cysteine residues, can undergo either
intramolecular disulfide bonding to form “compact monomers” or
intermolecular disulfide bonding to form aggregation-competent
dimers. Partially oxidized dimers, but not fully oxidized dimers, can
undergo further cysteine-dependent aggregation with reduced
monomers to form trimers, tetramers, and correspond larger
aggregates. (B) Tau K18 C291A/C322A/I260C contains a single
cysteine residue and for that matter can only form an oxidized dimer,
which cannot further aggregate via the cysteine-dependent pathway.
Since both proteins have intact hexapeptide motifs that also modulate
aggregation, it is proposed that the strong cysteine-dependent
aggregation tendency of tau K18 explains its overall higher
aggregation and filament-forming tendency compared to K18
C291A/C322A/I260C.
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knowledge, however, this is the first description of this
mechanism for a tau form. Notwithstanding their apparent
distinct principal filament formation mechanisms, K18 WT and
K18 C291A/C322A/I260C formed some filaments with the
same structural phenotypes. This raises the possibility that
filaments of the same structural phenotypes can be formed
through apparent heterogeneous aggregation paths.
Based on our findings, we propose a new model of cysteine-
dependent tau aggregation (Figure 10). In nonreducing
conditions, K18 WT can form either an intramolecular
disulfide bond (compact monomer) or an intermolecular
disulfide-based dimer as its least complex aggregate. Compact
monomers do not appear to impede aggregation, potentially
due to a low abundance or unfavorable formation in the
presence of heparin. Dimers can associate with reduced
monomers to form trimers and corresponding higher
aggregates by disulfide linkages. Partially oxidized dimers/
trimers/tetramers/larger oligomers can also cointeract through
disulfide bridges, therefore accelerating the rate of aggregation
(Figure 10). For K18 C291A/C322A/I260C, compact
monomer formation is not feasible, but a dimer is the only
cysteine-dependent aggregate it can form (Figure 10). Since
both constructs can theoretically undergo cysteine-independ-
ent aggregation to the same extent (each has intact
aggregation-promoting hexapeptide motifs in the MTBR), we
hypothesize that the stronger aggregation tendency of K18 WT
is conferred by its higher potential of cysteine-dependent
polymerization. It is currently unclear if these disulfide linkages
have any association with the filament assembly mechanisms
observed.
A limitation of this work is that even though the K18
fragment allows for accelerated aggregation, using this
truncated construct inevitably simplifies the otherwise more
complicated process for FL tau. Therefore, not all aspects of
the functional characterization described here for tau K18 may
apply to FL tau. Nonetheless, the described plasmids and
biochemical protocols will allow complementary FL tau
versions of the K18 constructs to be produced and
characterized.
In conclusion, we expect that the tau plasmid library and the
associated expression and purification protocols described
herein will facilitate future studies into the structural and
molecular determinants of the protein’s MT binding in
physiological conditions and aggregation in multiple diseases
and aid the design of effective inhibition agents. Moreover, the
new insights provided into the mechanistic basis of tau K18
filament polymorphisms should pave the way for further
studies exploring this knowledge for therapeutic gains.
■ METHODS
Materials. Heparin (#H3393), sodium phosphate dibasic
(#S9763), sodium phosphate monobasic dihydrate (#4269), and
thioflavin T (#T3516) were obtained from Sigma-Aldrich (St. Louis,
Missouri, USA). The QIAprep Spin Miniprep kit and the Q5 site-
directed mutagenesis kit (#E0554S) were bought from QIAGEN
GmbH (Hilden, Germany) and New England Biolabs (Ipswich,
Massachusetts, USA), respectively. The Bicinchoninic acid assay kit
(#786-570) was obtained from G-Biosciences (St. Louis, Missouri,
USA). The K9JA total tau antibody (#A0024) was purchased from
Dako (now Agilent), 77G7 (#816701) and Tau12 (#806501) were
purchased from BioLegend (San Diego, California, USA), and fast
flow resin with chelating sepharose (#17-0575-01) was purchased
from GE Healthcare (Buckinghamshire, UK). NuPAGE 4−12%
Novex Bis-Tris gels (#NP0321), 4× LDS (lithium dodecyl sulfate)
buffer (#NP0007), 20× MES (2-(N-morpholino)ethanesulfonic acid)
SDS running buffer (#NP0002), and 10× sample reducing agent
(#NP0004) were purchased from ThermoFisher. HRP-labeled
secondary antibody (#W4021) was purchased from Promega.
Isopropyl β-D-1-thiogalactopyranoside (IPTG; #I6758) and DNase I
(#04716728001) were purchased from Sigma, while BugBuster
(#70921) and protease inhibitor cocktail (#11836153001) were
purchased from Merck. BL21(DE3)*pRosetta cells and TEV protease
were kind gifts of Prof. David Roper and Dr. Deborah Brotherton,
respectively, both at the University of Warwick, Coventry, UK.
Plasmid Cloning, Protein Expression, and Purification.
Plasmid design, cloning, site-directed mutagenesis, transformation,
and DNA sequencing have been described elsewhere.59 Amino acid
changes made and primers used for site-directed mutagenesis have
been listed in Tables S2 and S3. Plasmids meant for open-access
sharing were prepared by transformation into BL21(DE3)*pRosetta
cells and amplified by overnight growth in Luria−Bertani broth
containing ampicillin (100 μg/mL) and chloramphenicol (35 μg/
mL), and the DNA was isolated using the QIAprep Spin Miniprep kit
following the manufacturer’s instructions. DNA concentration was
determined on a NanoDrop NP60 spectrophotometer. Mutagenic
changes were confirmed by aligning DNA sequencing chromatograms
against the template plasmid sequences using Genome Compiler
(Twist Bioscience, California, USA). Plasmid DNA aliquots are
available for sharing, allowing their transformation into the host of
choice. Details of plasmids can be found in Table S1.
Plasmids transformed into BL21(DE3)*pRosetta cells were
expressed and first purified by IMAC as described.59 Briefly, an
overnight culture of 10 mL of selective LB broth inoculated with
single colonies of BL21(DE3)*pRosetta cells encoding the tau
plasmid of interest was used to inoculate a 1 L fresh selective LB
broth. The cultures were grown at 37 °C with 180 rpm shaking until
the OD600 reached 0.6−07. After inducing expression with 0.5 mM
IPTG, the cultures were returned to the 37 °C shaking incubator for a
further 1 h. The cell lysates were harvested by centrifuging the
cultures at 9800 × g for 10 min at 4 °C. The recovered pellets were
resuspended in 50 mM sodium phosphate buffer pH 7.5 and frozen at
−20 °C until use. Immediately before purification, the lysates were
heated at 70 °C in the presence of the following reagents added per
50 mL lysate: 5 mL of 1× BugBuster, 10 mg DNase I, and 1 tablet
protease inhibitor cocktail. The mixtures were kept at room
temperature for 1 h and then sonicated (70% power, 1 min) in a
Bandelin Sonopuls 2070 sonicator and centrifuged (48000 × g, 30
min, 4 °C). The supernatant was decanted and filtered (0.2 μm)
before IMAC purification.
Chelating Sepharose resin packed into a Ni-NTA column (Bio-
Rad) was charged with 10 mM NiCl2/CH3COONa pH 4.0 buffer and
equilibrated with two column volumes (CVs) of buffer A (50 mM
sodium phosphate buffer pH 7.0, 500 mM NaCl, 10 mM imidazole).
After applying the crude extract (input), unbound protein was
removed in a two-step washing protocol, first with two CVs of buffer
A and then 2 CVs of buffer B (50 mM sodium phosphate buffer pH
7.0, 500 mM NaCl, 25 mM imidazole). His-tagged proteins were
eluted with buffer C (50 mM sodium phosphate buffer pH 7.0, 500
mM NaCl, 500 mM imidazole, 10 mM dithiothreitol). Selected
fractions, as analyzed by SDS-PAGE and Western blotting, were
pooled and concentrated by ultrafiltration using 3 and 10 kDa cutoff
centrifugal filter devices (Amicon) for K18 and FL tau, respectively.
All constructs were initially further purified by size exclusion
chromatography (SEC) on a Superdex S200 10/300 GL column
(#17-5175-01, GE Healthcare) running on an Ethan LC system (GE
Healthcare) with 1× PBS pH 7.4 as the running buffer. The molecular
weights of the fractions of interest were estimated using the elution
volumes of the following size markers from Sigma (#MWGF70-1KT):
blue dextran (2000 kDa; void volume), bovine serum albumin (66
kDa), carbonic anhydrase (29 kDa), cytochrome C (12.4 kDa), and
aprotinin (6.5 kDa). The optimized process showed that a SEC
polishing step was not necessary for K18 (data not shown). For all
constructs, the 6x-His tag was removed by overnight dialysis against
dialysis buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl) in the
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presence of 25 μg/mL TEV protease. The cleavage products were
separated by applying the dialyzed preparation to a charged resin
equilibrated as previously and collecting the cleaved tau as the flow-
through.
Western Blot. Equal volumes of SEC fractions were diluted in the
LDS sample buffer and the sample reducing agent and run in 4−12%
Bis-Tris protein gels in MES SDS running buffer (gel and buffers were
purchased from ThermoFisher Scientific; see the Materials section
above). The gels were subsequently equilibrated in transfer buffer
(20% methanol) for 25 min. Proteins were transferred to a
polyvinylidene fluoride membrane which had been previously
activated in pure methanol for 30 s and soaked in the transfer buffer
for another 25 min. Transfer was performed in a semidry blot
instrument at 0.8 mA/cm2 for 60 min at room temperature. The
membrane was then blocked for 1 h at room temperature using
PBST-BSA (PBS with 0.05% Tween 20 and 1% BSA) with gentle
shaking. Primary antibody incubation was performed overnight at 4
°C at a ratio of 1 μg of antibody per 1 mL of PBST-BSA. Afterward,
the membrane was washed three times with PBST (PBS with 0.05%
Tween 20), with each wash lasting 10 min with light shaking.
Secondary antibody was incubated at a ratio of 1 μL per 10 mL of
PBST-BSA for 1 h at room temperature with gentle shaking. Signal
detection was achieved by adding Amersham electrochemiluminiscent
detection reagents (GE Healthcare, Buckinghamshire, UK) and
imaging with the LAS 3000 camera system (Fujifilm). Western blot
characterization of the initial IMAC-based purification using the
MTBR-binding K9JA antibody followed a previously published
protocol.59
ThT Fluorescence Assay. Ten microliters each of heparin (MW
6000) and ThT (to yield 25 μM and 20 μM final concentrations,
respectively) was added to 80 μL of tau K18 (9 μM final
concentration) per well of a 96-well plate (Greiner Bio-One
#655077). Aggregation was monitored for 15 h by measuring ThT
fluorescence at 440 and 510 nm in a CLARIOstar microplate reader
(BMG Lab Tech, Ortenberg, Germany). Sensitivity was set to 20% to
prevent signal saturation. Reading using the top optic setting was
obtained every 5 min after 200 rpm shaking for 30 s. The ThT signal
at each time point was normalized to that of buffer only by subtracting
the absorbance value of the blank at each identical time point from
those of samples. Unless otherwise stated, the buffer used in all assays
was 10 mM sterile-filtered sodium phosphate buffer pH 7.4.
Filament Assembly and Characterization by Negative-Stain
TEM. Freshly purified samples (30 μM) were incubated with 63 μM
heparin for 5 or 16 days at 37 °C without shaking. Samples were then
diluted 1:2 with 10 mM sodium phosphate buffer pH 7.4 and
analyzed by TEM as described.59 The ImageJ freeware was used for
filament length and width analysis as follows: after setting the scale,
the freehand line tool was used to trace filament architecture, and the
length was then measured. The straight line tool was used for width
measurements. For filaments of apparently even width, measurements
were taken once from random positions. For those coalescing from
two filaments or of otherwise uneven widths, measurements were
taken from representative spots as described in Figure 9D. We
followed the terminology used by Xu et al. (2010)74 in characterizing
fibril structures.
CD Spectroscopy. Tau K18 samples (200 μL) diluted in 10 mM
sodium phosphate buffer pH 7.4 were transferred to a 1 mm path-
length cuvette and analyzed on a Jasco J-815 CD spectropolarimeter
(Jasco Inc., Maryland, USA) with 1 s response time, 0.1 nm data
pitch, and 100 nm/min scan speed. Averaged spectral accumulations
were collected at 190 to 280 nm wavelengths, with the high-tension
voltage maintained at ≤550 V.
CD analysis of monomers involved 15 μM K18 WT and K18
C291A/C322A/I260C. For time-dependent CD traces, data were
taken on 20 μM monomers on day 0 after which an 83 μM final
concentration of heparin was added, and the mixture was incubated at
37 °C without shaking. CD measurements were repeated on days 4
and 8. In sedimentation assays, filament samples were ultracentrifuged
at 100,000 × g for 1 h at 4 °C, the supernatant was removed, and the
pellet was resuspended in 200 μL of 10 mM sodium phosphate buffer
pH 7.4 for CD analysis.
Statistics. Data are expressed as mean ± standard error of the
mean (SEM) from n = 3 experiments, unless otherwise stated. Data
analysis and graph preparation were performed using Prism 7
(GraphPad Inc., California, USA). Statistical comparison of filament
features was performed using the Mann−Whitney test at the 95%
confidence interval, as the data did not follow Gaussian distribution.
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